HMF receives royalties from the Icahn School of Medicine at Mount Sinai and, in the past 3 years, has received advisory board fees from Alector, Otsuka Lundbeck, LifeWorx, and The Key. BV is an investigator in clinical trials sponsored by Biogen, Eli Lilly, Roche, Eisai, Pfizer, Pierre Fabre, and the Toulouse University Hospital. BV has served on an advisory board for Biogen, Alzheon, Green Valley, Novo Nordisk, Longeveron, and Rejuvenate Biomed and has received honoraria for consulting or serving on an advisory board from Roche, Eli Lilly, Eisai, TauRx, and Cerecin. YH declares there are no conflicts of interest. The Alzheimer’s Drug Discovery Foundation has funded or co-funded several projects to develop or clinically test the following drugs that are mentioned in the editorial: NTRX-07, dasatinib + quercetin, 5B8, TW001, LM11A-31-BHS, metformin, and semaglutide.